Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400303 · ClinicalTrials.gov registry record · Phase 1
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
A Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous, sponsored by Kyverna Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 2
- Study locations
NCT06400303 is a Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous that is active but no longer recruiting, run by Kyverna Therapeutics. The registered enrollment target is 3 participants, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06400303, a Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous, is active but no longer recruiting, sponsored by Kyverna Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
Conditions Studied
Interventions
- DRUG Standard lymphodepletion regimen
- BIOLOGICAL KYV-101
Study Locations (2)
California
- Stanford University Medical Center - Palo Alto
New York
- Northwell Health - Great Neck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06400303
The ClinicalTrials.gov registry entry for NCT06400303 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (99% lower). The listed sponsor is Kyverna Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Standard lymphodepletion regimen is the first listed.
NCT06400303 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT06400303 about?
NCT06400303 is a clinical study titled "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis". A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
What is the current status of trial NCT06400303?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2024-08-06. Estimated completion is 2027-03.
What conditions does trial NCT06400303 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria.
What interventions are being tested in trial NCT06400303?
The interventions under investigation include: Standard lymphodepletion regimen (DRUG), KYV-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06400303?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400303 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RECRUITING · Phase 1
Explore more on PlainTrial
Systemic Sclerosis
All registered trials for this condition
Systemic Sclerosis - Diffuse Cutaneous
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.